Free Trial

Ingevity (NGVT) to Release Quarterly Earnings on Tuesday

Ingevity logo with Basic Materials background

Ingevity (NYSE:NGVT - Get Free Report) is expected to be announcing its earnings results after the market closes on Tuesday, February 18th. Analysts expect the company to announce earnings of $0.29 per share and revenue of $297.40 million for the quarter. Investors interested in participating in the company's conference call can do so using this link.

Ingevity Stock Down 0.4 %

Shares of NYSE:NGVT traded down $0.18 during mid-day trading on Friday, reaching $45.01. 179,083 shares of the stock were exchanged, compared to its average volume of 181,741. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 6.52. The company has a market cap of $1.64 billion, a P/E ratio of -2.90 and a beta of 1.64. Ingevity has a one year low of $30.90 and a one year high of $56.29. The stock's 50 day simple moving average is $43.34 and its 200-day simple moving average is $40.91.

Wall Street Analysts Forecast Growth

Separately, BMO Capital Markets increased their price objective on Ingevity from $40.00 to $47.00 and gave the stock a "market perform" rating in a report on Thursday, October 31st. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $52.17.

Get Our Latest Stock Analysis on Ingevity

About Ingevity

(Get Free Report)

Ingevity Corporation manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. It operates through three segments: Performance Materials, Performance Chemicals, and Advanced Polymer Technologies.

Recommended Stories

Earnings History for Ingevity (NYSE:NGVT)

Should You Invest $1,000 in Ingevity Right Now?

Before you consider Ingevity, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ingevity wasn't on the list.

While Ingevity currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Goldman Sachs' 2025 Market Outlook: Top 3 Stock Picks

Goldman Sachs' 2025 Market Outlook: Top 3 Stock Picks

As Wall Street's 2025 predictions roll in, Goldman Sachs is focusing on manufacturing, energy, and domestic producers as key sectors for growth.

Recent Videos

NVIDIA Earnings: Will it Spark a Rally or Trigger a Sell-Off?
Marjorie Taylor Greene Bought THOUSANDS in Tesla Stock
The EXACT Date of Next Stock Market Crash

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines